The FDA will have to change the treatment development process to accelerate the entry of personalized, targeted medications into the market, Center for Drug Evaluation and Research Director Dr. Janet Woodcock told an audience at a luncheon hosted by the Personalized Medicine Coalition. A lot of thought needs to go into how to conduct trials of subsets of patients defined by biomarkers, she said.

Related Summaries